NCT03792841 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Amgen
Phase 1 Terminated
Clinical Trials
60 trialsNCT03294954 2025-09-19
GINAKIT2
Baylor College of Medicine
Phase 1 Recruiting
NCT03649061 2025-06-19
CareRA2020
Universitaire Ziekenhuizen KU Leuven
Phase 4 Completed
NCT04254627 2025-02-19
E/M
Nova Southeastern University
Phase 1 Active not recruiting
NCT03976245 2024-11-29
Advanced Therapeutics in Rheumatoid Arthritis (RA)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 4 Recruiting
NCT01793519 2024-02-28
STARA
Georgetown University
Phase 4 Unknown
NCT00585650 2023-08-18
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
University of California, Irvine
Phase 1/2 Completed
NCT00224393 2023-05-30
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
The Cleveland Clinic
Phase 2 Completed
NCT04798287 2022-06-22
STAR-RA-Cancer
Brigham and Women's Hospital
Completed
NCT05379049 2022-05-18
TNF-alpha
University of Sulaimani
Unknown
NCT04082910 2022-04-13
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT00421174 2021-11-01
BMTCTN0403
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00837434 2021-09-22
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT00566813 2021-04-06
Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression
University of Illinois at Chicago
Phase 1/2 Completed
NCT04115423 2020-09-10
A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab
Sungkyunkwan University
Unknown
NCT01060098 2020-01-18
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Imperial College London
Completed
NCT02364479 2019-12-19
Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein
Sun Yat-sen University
Phase 4 Completed
NCT02778789 2019-09-26
Re-Bone
University of Erlangen-Nürnberg Medical School
Completed
NCT03780959 2019-08-02
Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)
Amgen
Phase 2/3 Completed
NCT00205231 2019-03-22
A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease
University of Wisconsin, Madison
Phase NA Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01053819 2018-02-23
Can We Miss Pigmented Lesions in Psoriasis Patients?
University of Alabama at Birmingham
Phase 4 Completed
NCT00031551 2017-12-06
Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00201812 2017-12-06
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00201838 2017-11-30
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT00111956 2017-10-06
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2/3 Completed
NCT00309907 2017-09-29
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
Phase 2 Completed
NCT00001893 2017-07-02
Study of TNFR:Fc (Enbrel) in the Treatment of Asthma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01313221 2017-03-15
REFINE
Amgen
Phase 3 Completed
NCT00357903 2017-02-09
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Amgen
Phase 3 Completed
NCT00201682 2017-02-08
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT02109289 2017-02-07
Etanercept in Rheumatoid Arthritis and Vascular Inflammation
Innovaderm Research Inc.
Phase 4 Terminated
NCT01295151 2016-11-02
SWITCH
University of Leeds
Phase 4 Completed
NCT02878161 2016-08-25
Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"
Central South University
Phase 4 Unknown
NCT00141726 2015-12-03
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01730495 2015-12-02
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
Haukeland University Hospital
Phase 2 Terminated
NCT00724672 2015-06-01
A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)
Merck Sharp & Dohme LLC
Withdrawn
NCT02456363 2015-05-28
Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis
Chung Shan Medical University
Phase 2 Unknown
NCT00029328 2015-03-25
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
FDA Office of Orphan Products Development
Phase 1/2 Completed
NCT02376478 2015-03-03
On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection
Medical University of Vienna
Completed
NCT01009879 2013-07-02
Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants
University of Pittsburgh
Phase 4 Withdrawn
NCT00111449 2013-05-15
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
Amgen
Phase 3 Completed
NCT00111436 2013-04-26
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
Amgen
Phase 3 Completed
NCT00447265 2013-02-12
Etanercept for the Treatment of Lupus Nephritis
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Terminated
NCT00509600 2012-08-07
Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00127387 2012-06-26
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
The University of Texas Health Science Center at San Antonio
Phase 2/3 Terminated
NCT00093366 2011-11-30
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00112385 2011-06-21
A Pilot Study of Etanercept in Dermatomyositis
Brigham and Women's Hospital
Phase 1 Completed
NCT00046904 2011-05-05
Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer
Mayo Clinic
Phase 3 Completed